DMAA
Drugs Made In·NASDAQ
--
--(--)
--
--(--)
DMAA fundamentals
Drugs Made In (DMAA) released its earnings on Nov 18, 2025: revenue was -- (YoY 0.00%), beat estimates; EPS was 0.0652 (YoY +485.80%), missed estimates.
Revenue / YoY
--
0.00%
EPS / YoY
0.0652
+485.80%
Report date
Nov 18, 2025
EPS
Revenue
Revenue & Expenses
Key Indicators
Drugs Made In (DMAA) key financial stats and ratios, covering profitability, financial health, and leverage.
Drugs Made In (DMAA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Drugs Made In (DMAA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Drugs Made In (DMAA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Drugs Made In (DMAA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Drugs Made In (DMAA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is Drugs Made In's gross profit margin?What is Drugs Made In's latest dividend and current dividend yield?What were the key takeaways from Drugs Made In's earnings call?What is the market's earnings forecast for Drugs Made In next quarter?What guidance did Drugs Made In's management provide for the next earnings period?What is the revenue and EPS growth rate for Drugs Made In year over year?What were the key takeaways from Drugs Made In’s earnings call?What factors drove the changes in Drugs Made In's revenue and profit?
